Floortje J. Backes, MD

Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.

Floortje J. Backes, MD, discusses other potential roles for mirvetuximab soravtansine and other antibody-drug conjugates in ovarian cancer.

Floortje J. Backes, MD, discusses data for mirvetuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer

Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.

Floortje J Backes, MD, discusses how mirvetuximab soravtansine has affected the management of platinum-resistant ovarian cancer.

Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.

Floor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation.

Looking ahead, Floor Backes, MD, notes that key needs in the treatment of advanced endometrial cancer are figuring out next steps when immunotherapy resistance develops, targeted radiation for oligometastatic disease, and sorting patients into subgroups for personalize care.

Floor Backes, MD, and Matthew Powell, MD, review data on sacituzumab govitecan, an antibody-drug conjugate targeting topoisomerase in patients with advanced endometrial cancer.

Drs Backes and Powell discuss the management of adverse events between upfront immunotherapy versus chemotherapy followed by later immunotherapy for endometrial cancer, noting the need for molecular subgroup data from trials like LEAP-001.

Matthew Powell, MD, and Floor Backes, MD, discuss real-world evidence from recent trials confirming benefit of immunotherapies in practice for patients with advanced endometrial cancer.

Drs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance.

Matthew Powell, MD, and Floor Backes, MD, enthusiastically discuss the practice-changing RUBY trial results presented at the 2023 ESMO Congress showing impressive survival benefits with immunotherapy plus chemotherapy for both MMR-deficient and MMR-proficient advanced endometrial cancer.

Experts review data on single-agent immunotherapy in patients with endometrial cancer from recent conferences, including ASCO 2023.

Drs Backes and Powell highlight key advances in endometrial cancer treatment from the 2023 SGO, ASCO, and ESMO conferences, including HER2-targeted therapies showing promising response rates.

Matthew Powell, MD, and Floor Backes, MD, discuss recent advances in the molecular profiling and staging of endometrial cancer.

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

Floor J. Backes, MD, discusses the role of PARP inhibitors as treatment of patients with ovarian cancer and her experience with these agents, such as rucaparib.

Floor J. Backes, MD, discusses quality of life with PARP inhibitors for patients with ovarian cancer.

Floor J. Backes, MD, discusses toxicity considerations with PARP inhibitors in ovarian cancer.

Floor J. Backes, MD, discusses the consideration of financial toxicity when choosing a PARP inhibitor for a patient with ovarian cancer.

Floor J. Backes, MD, discusses the phase III FILM trial in endometrial cancer.

Floor J. Backes, MD, discusses the safety profile from a phase I study looking at lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses treatment selection with PARP inhibitors in ovarian cancer.

Floor J. Backes, MD, discusses the next steps regarding a phase I trial investigating lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Floor J. Backes, MD, discusses the rationale and results from a phase I study exploring lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, at The Ohio State University Comprehensive Cancer Center, discusses the utility of sentinel lymph node mapping in patients with cervical cancer.

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, at The Ohio State University Comprehensive Cancer Center, discusses the use of sentinel lymph node mapping in patients with cervical cancer.

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses combinations with PARP inhibitors in the treatment of patients with ovarian cancer.